{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T18:08:17Z","timestamp":1790359697305,"version":"4.1.0"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,10,28]],"date-time":"2018-10-28T00:00:00Z","timestamp":1540684800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Drug Investig"],"published-print":{"date-parts":[[2019,1]]},"DOI":"10.1007\/s40261-018-0719-0","type":"journal-article","created":{"date-parts":[[2018,10,28]],"date-time":"2018-10-28T09:44:00Z","timestamp":1540719840000},"page":"27-43","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Safety and Efficacy Profile of Neratinib: A Systematic Review and Meta-Analysis of 23 Prospective Clinical Trials"],"prefix":"10.1007","volume":"39","author":[{"given":"Zhihang","family":"Tao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stanley Xiangyu","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunuo","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9148-5001","authenticated-orcid":false,"given":"Xuelei","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,10,28]]},"reference":[{"issue":"4785","key":"719_CR1","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1126\/science.3798106","volume":"235","author":"DJ Slamon","year":"1987","unstructured":"Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2\/neu oncogene. Science. 1987;235(4785):177\u201382.","journal-title":"Science"},{"issue":"4905","key":"719_CR2","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1126\/science.2470152","volume":"244","author":"DJ Slamon","year":"1989","unstructured":"Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, et al. Studies of the HER-2\/neu proto-oncogene in human breast and ovarian cancer. Science. 1989;244(4905):707\u201312.","journal-title":"Science"},{"issue":"9","key":"719_CR3","doi-asserted-by":"publisher","first-page":"2639","DOI":"10.1200\/JCO.1999.17.9.2639","volume":"17","author":"MA Cobleigh","year":"1999","unstructured":"Cobleigh MA, Vogel CL, Tripathy D, Robert NJ, Scholl S, Fehrenbacher L, et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol. 1999;17(9):2639\u201348.","journal-title":"J Clin Oncol"},{"issue":"3","key":"719_CR4","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1200\/JCO.2002.20.3.719","volume":"20","author":"CL Vogel","year":"2002","unstructured":"Vogel CL, Cobleigh MA, Tripathy D, Gutheil JC, Harris LN, Fehrenbacher L, et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol. 2002;20(3):719\u201326.","journal-title":"J Clin Oncol"},{"issue":"3","key":"719_CR5","doi-asserted-by":"publisher","first-page":"348","DOI":"10.2174\/1871520610909030348","volume":"9","author":"SM Tolaney","year":"2009","unstructured":"Tolaney SM, Krop IE. Mechanisms of trastuzumab resistance in breast cancer. Anticancer Agents Med Chem. 2009;9(3):348\u201355.","journal-title":"Anticancer Agents Med Chem"},{"issue":"9","key":"719_CR6","doi-asserted-by":"publisher","first-page":"793","DOI":"10.4161\/cbt.11.9.15045","volume":"11","author":"JT Garrett","year":"2011","unstructured":"Garrett JT, Arteaga CL. Resistance to HER2-directed antibodies and tyrosine kinase inhibitors: mechanisms and clinical implications. Cancer Biol Ther. 2011;11(9):793\u2013800.","journal-title":"Cancer Biol Ther"},{"issue":"11","key":"719_CR7","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1056\/NEJM200103153441101","volume":"344","author":"DJ Slamon","year":"2001","unstructured":"Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344(11):783\u201392.","journal-title":"N Engl J Med"},{"issue":"5","key":"719_CR8","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1200\/JCO.2002.20.5.1215","volume":"20","author":"A Seidman","year":"2002","unstructured":"Seidman A, Hudis C, Pierri MK, Shak S, Paton V, Ashby M, et al. Cardiac dysfunction in the trastuzumab clinical trials experience. J Clin Oncol. 2002;20(5):1215\u201321.","journal-title":"J Clin Oncol"},{"key":"719_CR9","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.breast.2017.10.010","volume":"37","author":"DM Gujral","year":"2018","unstructured":"Gujral DM, Lloyd G, Bhattacharyya S. Effect of prophylactic betablocker or ACE inhibitor on cardiac dysfunction and heart failure during anthracycline chemotherapy\u2009\u00b1\u2009trastuzumab. Breast. 2018;37:64\u201371.","journal-title":"Breast"},{"issue":"11","key":"719_CR10","doi-asserted-by":"publisher","first-page":"3958","DOI":"10.1158\/0008-5472.CAN-03-2868","volume":"64","author":"SK Rabindran","year":"2004","unstructured":"Rabindran SK, Discafani CM, Rosfjord EC, Baxter M, Floyd MB, Golas J, et al. Antitumor activity of HKI-272, an orally active, irreversible inhibitor of the HER-2 tyrosine kinase. Cancer Res. 2004;64(11):3958\u201365.","journal-title":"Cancer Res"},{"issue":"7","key":"719_CR11","doi-asserted-by":"publisher","first-page":"2552","DOI":"10.1158\/1078-0432.CCR-08-1978","volume":"15","author":"KK Wong","year":"2009","unstructured":"Wong KK, Fracasso PM, Bukowski RM, Lynch TJ, Munster PN, Shapiro GI, et al. A phase I study with neratinib (HKI-272), an irreversible pan ErbB receptor tyrosine kinase inhibitor, in patients with solid tumors. Clin Cancer Res. 2009;15(7):2552\u20138.","journal-title":"Clin Cancer Res"},{"issue":"8","key":"719_CR12","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1200\/JCO.2009.25.8707","volume":"28","author":"HJ Burstein","year":"2010","unstructured":"Burstein HJ, Sun Y, Dirix LY, Jiang Z, Paridaens R, Tan AR, et al. Neratinib, an irreversible ErbB receptor tyrosine kinase inhibitor, in patients with advanced ErbB2-positive breast cancer. J Clin Oncol. 2010;28(8):1301\u20137.","journal-title":"J Clin Oncol"},{"issue":"10","key":"719_CR13","doi-asserted-by":"publisher","first-page":"1592","DOI":"10.18632\/oncotarget.1148","volume":"4","author":"A Canonici","year":"2013","unstructured":"Canonici A, Gijsen M, Mullooly M, Bennett R, Bouguern N, Pedersen K, et al. Neratinib overcomes trastuzumab resistance in HER2 amplified breast cancer. Oncotarget. 2013;4(10):1592\u2013605.","journal-title":"Oncotarget."},{"issue":"1","key":"719_CR14","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1093\/annonc\/mds284","volume":"24","author":"A Awada","year":"2013","unstructured":"Awada A, Dirix L, Manso Sanchez L, Xu B, Luu T, Dieras V, et al. Safety and efficacy of neratinib (HKI-272) plus vinorelbine in the treatment of patients with ErbB2-positive metastatic breast cancer pretreated with anti-HER2 therapy. Ann Oncol. 2013;24(1):109\u201316.","journal-title":"Ann Oncol"},{"issue":"10","key":"719_CR15","doi-asserted-by":"publisher","first-page":"1985","DOI":"10.1038\/bjc.2013.178","volume":"108","author":"LW Chow","year":"2013","unstructured":"Chow LW, Xu B, Gupta S, Freyman A, Zhao Y, Abbas R, et al. Combination neratinib (HKI-272) and paclitaxel therapy in patients with HER2-positive metastatic breast cancer. Br J Cancer. 2013;108(10):1985\u201393.","journal-title":"Br J Cancer"},{"issue":"6","key":"719_CR16","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1007\/s00280-013-2262-2","volume":"72","author":"RC Jankowitz","year":"2013","unstructured":"Jankowitz RC, Abraham J, Tan AR, Limentani SA, Tierno MB, Adamson LM, et al. Safety and efficacy of neratinib in combination with weekly paclitaxel and trastuzumab in women with metastatic HER2positive breast cancer: an NSABP Foundation Research Program phase I study. Cancer Chemother Pharmacol. 2013;72(6):1205\u201312.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"18","key":"719_CR17","doi-asserted-by":"publisher","first-page":"3763","DOI":"10.1016\/j.ejca.2013.07.142","volume":"49","author":"M Martin","year":"2013","unstructured":"Martin M, Bonneterre J, Geyer CE Jr, Ito Y, Ro J, Lang I, et al. A phase two randomised trial of neratinib monotherapy versus lapatinib plus capecitabine combination therapy in patients with HER2\u2009+\u2009advanced breast cancer. Eur J Cancer. 2013;49(18):3763\u201372.","journal-title":"Eur J Cancer"},{"issue":"12","key":"719_CR18","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.1001\/jamaoncol.2016.0237","volume":"2","author":"A Awada","year":"2016","unstructured":"Awada A, Colomer R, Inoue K, Bondarenko I, Badwe RA, Demetriou G, et al. Neratinib plus paclitaxel vs trastuzumab plus paclitaxel in previously untreated metastatic ERBB2-positive breast cancer: the nefert-t randomized clinical trial. JAMA Oncol. 2016;2(12):1557\u201364.","journal-title":"JAMA Oncol."},{"issue":"32","key":"719_CR19","doi-asserted-by":"publisher","first-page":"3626","DOI":"10.1200\/JCO.2014.56.3809","volume":"32","author":"C Saura","year":"2014","unstructured":"Saura C, Garcia-Saenz JA, Xu B, Harb W, Moroose R, Pluard T, et al. Safety and efficacy of neratinib in combination with capecitabine in patients with metastatic human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol. 2014;32(32):3626\u201333.","journal-title":"J Clin Oncol"},{"issue":"12","key":"719_CR20","doi-asserted-by":"publisher","first-page":"1688","DOI":"10.1016\/S1470-2045(17)30717-9","volume":"18","author":"M Martin","year":"2017","unstructured":"Martin M, Holmes FA, Ejlertsen B, Delaloge S, Moy B, Iwata H, et al. Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2017;18(12):1688\u2013700.","journal-title":"Lancet Oncol."},{"issue":"18","key":"719_CR21","doi-asserted-by":"publisher","first-page":"3076","DOI":"10.1200\/JCO.2009.27.9414","volume":"28","author":"LV Sequist","year":"2010","unstructured":"Sequist LV, Besse B, Lynch TJ, Miller VA, Wong KK, Gitlitz B, et al. Neratinib, an irreversible pan-ErbB receptor tyrosine kinase inhibitor: results of a phase II trial in patients with advanced non-small-cell lung cancer. J Clin Oncol. 2010;28(18):3076\u201383.","journal-title":"J Clin Oncol"},{"issue":"9","key":"719_CR22","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1200\/JCO.2015.63.0343","volume":"34","author":"RA Freedman","year":"2016","unstructured":"Freedman RA, Gelman RS, Wefel JS, Melisko ME, Hess KR, Connolly RM, et al. Translational Breast Cancer Research Consortium (TBCRC) 022: a phase II trial of Neratinib for patients with human epidermal growth factor receptor 2-positive breast cancer and brain metastases. J Clin Oncol. 2016;34(9):945\u201352.","journal-title":"J Clin Oncol"},{"issue":"19","key":"719_CR23","doi-asserted-by":"publisher","first-page":"5687","DOI":"10.1158\/1078-0432.CCR-17-0900","volume":"23","author":"CX Ma","year":"2017","unstructured":"Ma CX, Bose R, Gao F, Freedman RA, Telli ML, Kimmick G, et al. Neratinib efficacy and circulating tumor DNA detection of HER2 mutations in HER2 nonamplified metastatic breast cancer. Clin Cancer Res. 2017;23(19):5687\u201395.","journal-title":"Clin Cancer Res"},{"issue":"2","key":"719_CR24","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1200\/JCO.2012.47.2787","volume":"32","author":"L Gandhi","year":"2014","unstructured":"Gandhi L, Bahleda R, Tolaney SM, Kwak EL, Cleary JM, Pandya SS, et al. Phase I study of neratinib in combination with temsirolimus in patients with human epidermal growth factor receptor 2-dependent and other solid tumors. J Clin Oncol. 2014;32(2):68\u201375.","journal-title":"J Clin Oncol"},{"issue":"1","key":"719_CR25","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1007\/s00280-012-1857-3","volume":"70","author":"R Abbas","year":"2012","unstructured":"Abbas R, Hug BA, Leister C, Sonnichsen D. A double-blind, randomized, multiple-dose, parallel-group study to characterize the occurrence of diarrhea following two different dosing regimens of neratinib, an irreversible pan-ErbB receptor tyrosine kinase inhibitor. Cancer Chemother Pharmacol. 2012;70(1):191\u20139.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"4","key":"719_CR26","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1093\/jjco\/hys012","volume":"42","author":"Y Ito","year":"2012","unstructured":"Ito Y, Suenaga M, Hatake K, Takahashi S, Yokoyama M, Onozawa Y, et al. Safety, efficacy and pharmacokinetics of neratinib (HKI-272) in Japanese patients with advanced solid tumors: a phase 1 dose-escalation study. Jpn J Clin Oncol. 2012;42(4):278\u201386.","journal-title":"Jpn J Clin Oncol"},{"issue":"1","key":"719_CR27","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1513750","volume":"375","author":"JW Park","year":"2016","unstructured":"Park JW, Liu MC, Yee D, Yau C, van\u2019t Veer LJ, Symmans WF, et al. Adaptive randomization of Neratinib in early breast cancer. N Engl J Med. 2016;375(1):11\u201322.","journal-title":"N Engl J Med."},{"issue":"15S","key":"719_CR28","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1200\/jco.2009.27.15_suppl.1004","volume":"27","author":"R Swaby","year":"2009","unstructured":"Swaby R, Blackwell K, Jiang Z, Sun Y, Dieras V, Zaman K, et al. Neratinib in combination with trastuzumab for the treatment of advanced breast cancer: a phase I\/II study. J Clin Oncol. 2009;27(15S):1004.","journal-title":"J Clin Oncol"},{"key":"719_CR29","doi-asserted-by":"crossref","unstructured":"Gajria D, King T, Pannu H, Sakr R, Seidman AD, Modi S, et al. Combined Inhibition of mTORC1 with temsirolimus and HER2 with neratinib: a phase I\/II study in patients with metastatic HER2-amplified or triple-negative breast cancer. Cancer Res. 2011;71(24 Suppl). http:\/\/cancerres.aacrjournals.org\/content\/71\/24_Supplement\/PD09-08 .","DOI":"10.1158\/0008-5472.SABCS11-PD09-08"},{"issue":"15 Suppl","key":"719_CR30","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1200\/JCO.2017.35.15_suppl.1005","volume":"35","author":"RA Freedman","year":"2017","unstructured":"Freedman RA, Gelman RS, Melisko ME, Anders CK, Moy B, Blackwell KL, et al. TBCRC 022: phase II trial of neratinib\u2009+\u2009capecitabine for patients with human epidermal growth factor receptor 2-positive (HER2+) breast cancer brain metastases. J Clin Oncol. 2017;35(15 Suppl):1005.","journal-title":"J Clin Oncol"},{"key":"719_CR31","doi-asserted-by":"crossref","unstructured":"Barcenas C, Olek E, Hunt D, Tripathy D, Ibrahim E, Wilkinson M et al. Incidence and severity of diarrhea with neratinib plus intensive loperamide prophylaxis in patients (pts) with HER2+\u2009early-stage breast cancer (EBC): interim analysis from the multicenter, open-label, phase II control trial. Cancer Res. 2017;77(4 Suppl).","DOI":"10.1158\/1538-7445.SABCS16-P2-11-03"},{"issue":"1","key":"719_CR32","doi-asserted-by":"publisher","first-page":"S358","DOI":"10.1016\/j.jtho.2016.11.398","volume":"12","author":"L Gandhi","year":"2017","unstructured":"Gandhi L, Besse B, Mazieres J, Waciar S, Cortot A, Barlesi F, et al. Neratinib\u2009\u00b1\u2009temsirolimus in HER2-mutant lung cancers: an international, randomized phase II study. J Thorac Oncol. 2017;12(1):S358\u20139.","journal-title":"J Thorac Oncol."},{"key":"719_CR33","doi-asserted-by":"crossref","unstructured":"Hyman D, Piha-Paul S, Saura C, Arteaga C, Mayer I, Shapiro G, et al. Neratinib plus fulvestrant in ERBB2-mutant, HER2-non-amplified, estrogen receptor (ER)-positive, metastatic breast cancer (MBC): preliminary analysis from the phase II SUMMIT trial. Cancer Res. 2017;77(4 Suppl).","DOI":"10.1158\/1538-7445.SABCS16-PD2-08"},{"key":"719_CR34","doi-asserted-by":"crossref","unstructured":"Onozawa Y, Watanabe J, Yamamoto N, Boku N, Suzuki M, Takenake N et al. A Phase 1 Study of Neratinib in combination with Vinorelbine in Japanese patients with advanced or metastatic solid tumours. European Journal of Cancer. 2011;47:S350-S.","DOI":"10.1016\/S0959-8049(11)71509-X"},{"issue":"4","key":"719_CR35","doi-asserted-by":"publisher","first-page":"305","DOI":"10.2165\/00002512-199812040-00005","volume":"12","author":"LR Wiseman","year":"1998","unstructured":"Wiseman LR, Spencer CM. Paclitaxel. An update of its use in the treatment of metastatic breast cancer and ovarian and other gynaecological cancers. Drugs Aging. 1998;12(4):305\u201334.","journal-title":"Drugs Aging."},{"issue":"6 Pt 1","key":"719_CR36","first-page":"G807","volume":"260","author":"K Opleta-Madsen","year":"1991","unstructured":"Opleta-Madsen K, Hardin J, Gall DG. Epidermal growth factor upregulates intestinal electrolyte and nutrient transport. Am J Physiol. 1991;260(6 Pt 1):G807\u201314.","journal-title":"Am J Physiol"},{"issue":"9","key":"719_CR37","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1136\/gut.32.9.994","volume":"32","author":"RA Goodlad","year":"1991","unstructured":"Goodlad RA, Raja KB, Peters TJ, Wright NA. Effects of urogastrone-epidermal growth factor on intestinal brush border enzymes and mitotic activity. Gut. 1991;32(9):994\u20138.","journal-title":"Gut"},{"issue":"11","key":"719_CR38","first-page":"13","volume":"11","author":"F Ustaris","year":"2015","unstructured":"Ustaris F, Saura C, Di Palma J, Bryce R, Moran S, Neuman L, et al. Effective management and prevention of Neratinib-induced diarrhea. Am J Hematol Oncol. 2015;11(11):13\u201322.","journal-title":"Am J Hematol Oncol."},{"issue":"10","key":"719_CR39","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1177\/0003319714523112","volume":"65","author":"A Dirican","year":"2014","unstructured":"Dirican A, Levent F, Alacacioglu A, Kucukzeybek Y, Varol U, Kocabas U, et al. Acute cardiotoxic effects of adjuvant trastuzumab treatment and its relation to oxidative stress. Angiology. 2014;65(10):944\u20139.","journal-title":"Angiology"},{"issue":"15","key":"719_CR40","doi-asserted-by":"publisher","first-page":"4016","DOI":"10.1158\/1078-0432.CCR-10-0280","volume":"16","author":"B Hug","year":"2010","unstructured":"Hug B, Abbas R, Leister C, Burns J, Sonnichsen D. A single-dose, crossover, placebo- and moxifloxacin-controlled study to assess the effects of neratinib (HKI-272) on cardiac repolarization in healthy adult subjects. Clin Cancer Res. 2010;16(15):4016\u201323.","journal-title":"Clin Cancer Res"},{"issue":"7","key":"719_CR41","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1200\/JCO.2008.21.4437","volume":"28","author":"KL Blackwell","year":"2010","unstructured":"Blackwell KL, Burstein HJ, Storniolo AM, Rugo H, Sledge G, Koehler M, et al. Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer. J Clin Oncol. 2010;28(7):1124\u201330.","journal-title":"J Clin Oncol"},{"issue":"2","key":"719_CR42","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/j.ctrv.2013.09.002","volume":"40","author":"I Kumler","year":"2014","unstructured":"Kumler I, Tuxen MK, Nielsen DL. A systematic review of dual targeting in HER2-positive breast cancer. Cancer Treat Rev. 2014;40(2):259\u201370.","journal-title":"Cancer Treat Rev"},{"issue":"5","key":"719_CR43","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1007\/s10637-010-9415-5","volume":"29","author":"N O\u2019Donovan","year":"2011","unstructured":"O\u2019Donovan N, Byrne AT, O\u2019Connor AE, McGee S, Gallagher WM, Crown J. Synergistic interaction between trastuzumab and EGFR\/HER-2 tyrosine kinase inhibitors in HER-2 positive breast cancer cells. Investig New Drugs. 2011;29(5):752\u20139.","journal-title":"Investig New Drugs"},{"issue":"17","key":"719_CR44","doi-asserted-by":"publisher","first-page":"3608","DOI":"10.1200\/JCO.2004.01.175","volume":"22","author":"NU Lin","year":"2004","unstructured":"Lin NU, Bellon JR, Winer EP. CNS metastases in breast cancer. J Clin Oncol. 2004;22(17):3608\u201317.","journal-title":"J Clin Oncol"},{"issue":"9","key":"719_CR45","doi-asserted-by":"publisher","first-page":"1837","DOI":"10.1002\/cncr.25771","volume":"117","author":"A Musolino","year":"2011","unstructured":"Musolino A, Ciccolallo L, Panebianco M, Fontana E, Zanoni D, Bozzetti C, et al. Multifactorial central nervous system recurrence susceptibility in patients with HER2-positive breast cancer: epidemiological and clinical data from a population-based cancer registry study. Cancer. 2011;117(9):1837\u201346.","journal-title":"Cancer"},{"issue":"16","key":"719_CR46","doi-asserted-by":"publisher","first-page":"1700","DOI":"10.1016\/S1470-2045(15)00373-3","volume":"16","author":"J Cortes","year":"2015","unstructured":"Cortes J, Dieras V, Ro J, Barriere J, Bachelot T, Hurvitz S, et al. Afatinib alone or afatinib plus vinorelbine versus investigator\u2019s choice of treatment for HER2-positive breast cancer with progressive brain metastases after trastuzumab, lapatinib, or both (LUX-Breast 3): a randomised, open-label, multicentre, phase 2 trial. Lancet Oncol. 2015;16(16):1700\u201310.","journal-title":"Lancet Oncol."},{"issue":"2","key":"719_CR47","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1053\/j.seminoncol.2017.06.006","volume":"44","author":"CC O\u2019Sullivan","year":"2017","unstructured":"O\u2019Sullivan CC, Davarpanah NN, Abraham J, Bates SE. Current challenges in the management of breast cancer brain metastases. Semin Oncol. 2017;44(2):85\u2013100.","journal-title":"Semin Oncol"},{"issue":"3","key":"719_CR48","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/S1470-2045(15)00551-3","volume":"17","author":"A Chan","year":"2016","unstructured":"Chan A, Delaloge S, Holmes FA, Moy B, Iwata H, Harvey VJ, et al. Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2016;17(3):367\u201377.","journal-title":"Lancet Oncol."},{"issue":"6","key":"719_CR49","doi-asserted-by":"publisher","first-page":"R121","DOI":"10.1186\/bcr3067","volume":"13","author":"YC Wang","year":"2011","unstructured":"Wang YC, Morrison G, Gillihan R, Guo J, Ward RM, Fu X, et al. Different mechanisms for resistance to trastuzumab versus lapatinib in HER2-positive breast cancers\u2014role of estrogen receptor and HER2 reactivation. Breast Cancer Res. 2011;13(6):R121.","journal-title":"Breast Cancer Res"},{"key":"719_CR50","doi-asserted-by":"publisher","first-page":"S125","DOI":"10.1016\/S0959-8049(16)32971-9","volume":"69","author":"M Scaltriti","year":"2016","unstructured":"Scaltriti M, Carmona FJ, Toska E, Cocco E, Hyman D, Cutler R, et al. Neratinib induces estrogen receptor function and sensitizes HER2-mutant breast cancer to anti-endocrine therapy. Eur J Cancer. 2016;69:S125.","journal-title":"Eur J Cancer."}],"container-title":["Clinical Drug Investigation"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40261-018-0719-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-018-0719-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-018-0719-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,14]],"date-time":"2020-11-14T05:28:48Z","timestamp":1605331728000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40261-018-0719-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10,28]]},"references-count":50,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,1]]}},"alternative-id":["719"],"URL":"https:\/\/doi.org\/10.1007\/s40261-018-0719-0","relation":{},"ISSN":["1173-2563","1179-1918"],"issn-type":[{"value":"1173-2563","type":"print"},{"value":"1179-1918","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,10,28]]},"assertion":[{"value":"28 October 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"There was no funding associated with the completion of this work.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Zhihang Tao, Stanley Xiangyu Li, Kai Shen, Yunuo Zhao, Hao Zeng, and Xuelei Ma declare that they have no conflicts of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}